Sign in
TerminatedNo phase

Evaluation of Effectiveness and Safety of Hybrid Coronary Revascularization

Key facts

Who runs it
Seung-Jung Park
Where
South Korea1 site in 1 countryChoose a country to see its sites
Trial code
Status
Terminated
People taking part
6 people enrolled
Started
5 Apr 2019
Ended
13 Apr 2026
Type of study
Observational
Treatments tested
  • Hybrid Coronary Revascularization
Record updated
15 April 2026
Why it stopped
Early termination due to low enrollment

Who can take part

Age
20 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 5 criteriaShow less

Who can take part

  • Age 20 and more
  • Hybrid coronary revascularization due to multivessel coronary artery disease(must include left anterior descending artery)
  • Written consent

Who cannot take part

  • Previous CABG(coronary artery bypass graft)
  • Life expectancy ≤1 year

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This study evaluated the effectiveness and safety of Hybrid Coronary Revascularization in real-world practice.

The group in the trial

  • Multivessel coronary artery disease

    must include left anterior descending artery

    Treatment: Hybrid Coronary Revascularization

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Evaluation of Effectiveness and Safety of Hybrid Coronary Revascularization, a Non-randomized, Prospective, Open-label Registry in Real-world Practice
Record updated
15 April 2026